AtaiBeckley
Manufacturing · Netherlands · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Prof. J.h. Bavincklaan 7, Amstelveen, No...Phone Number
+31 207932536Website
www.ataibeckley.comRevenue
<$5 MillionStock Symbol
ATAIIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About AtaiBeckley
AtaiBeckley is a clinical-stage biopharmaceutical company headquartered in New York and Amsterdam, focused on developing rapid-acting and convenient mental health treatments to transform patient outcomes. Formed through the strategic combination of atai Life Sciences and Beckley Psytech Limited completed in November 2025, the company brings together world-class science and clinical expertise with a pipeline of investigational psychedelic-based neuroplastogens designed to address urgent unmet needs in mental health. AtaiBeckley's lead program is BPL-003, a novel mebufotenin benzoate nasal spray designed to produce rapid and durable antidepressive effects from a single dose for treatment-resistant depression, which has received Breakthrough Therapy designation from the FDA and is Phase 3-ready. The company's diversified pipeline also includes VLS-01, a DMT buccal film for treatment-resistant depression currently in Phase 2 clinical trials, EMP-01, an oral R-MDMA being evaluated for sociaRead more
Popular SearchesAtaiBeckley NVSIC Code 28,283NAICS Code 32,325Ticker NASDAQ: ATAIShow moreAtaiBeckley Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AtaiBeckley your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on AtaiBeckley recently announced quarterly report
Funding: Get notified immidiatlly once AtaiBeckley has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
AtaiBeckley, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if AtaiBeckley is spiking on competitors!
Click to see if AtaiBeckley had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at AtaiBeckley
Check if AtaiBeckley has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when AtaiBeckley launches new products
Recommended Actions
Reach out to Masked Content who joined AtaiBeckley as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
AtaiBeckley is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
AtaiBeckley is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about AtaiBeckley.
Most Recent Scoops
Project
observed in the EMP-01 study that patients showed behavior change by six weeks, with improvements in both fear response and avoidance behaviors, the latter changing more quickly in a pattern similar to cognitive behavioral therapy.
Medical Research
Project
AtaiBeckley is conducting a Phase 2b trial for VLS-01 with approximately 142 patients across two arms (71 patients each), using a two-dose induction regimen with doses two weeks apart, a primary endpoint at four weeks, and 12 weeks of follow-up.
Medical Research, Pharmaceuticals, Clinical Operations
Project
AtaiBeckley has completed a Phase IIb study for BPL-003 with approximately 75 patients in two arms (12-milligram high dose and 0.3-milligram low dose) and 45 patients in the intermediate 8-milligram dose arm, with results reported in July of last year.
Medical Research, Pharmaceuticals, Clinical Operations
Project
reported that patients receiving 8-milligram BPL-003 followed by 12-milligram in the open label extension showed continued improvement, with remission rates of approximately 80% and response rates of roughly 66% at the end of 16 weeks with 2 doses total.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Medical Research, Pharmaceuticals, Clinical Operations
AtaiBeckley News & Media
Atai Beckley N.V. (ATAI) A Top Penny Stock to Buy Poised to Build Sustained Clinical and Shareholder Value
Atai Beckley N.V. (NASDAQ:ATAI) is one of the top penny stocks to buy in investors’ stock portfolio. On May 12, ATAI Beckley (NASDAQ:ATAI) delivered solid first-quarter results and a business update as it continues to develop its pipeline. The company remains on track to proceed with the Phase 3 Pivotal program for BPL-003, a proprietary […]AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations
AtaiBeckley launches Patient Impact Grant Program, which will award three grants of $20,000 each to non-profit organizations in mental healthAtaiBeckley to Participate in Upcoming Investor Conferences in June 2026
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that members of the Company’s management team will participate in multiple upcoming investor conferences in June 2026.AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today reported financial results for the first quarter ended March 31, 2026, and provided a business update across its clinical pipeline.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AtaiBeckley
Sign Up For FreeTo access detailed company insights
AtaiBeckley is a clinical-stage biopharmaceutical company headquartered in New York and Amsterdam, focused on developing rapid-acting and convenient mental health treatments to transform patient outcomes. Formed through the strategic combination of atai Life Sciences and Beckley Psytech Limited completed in November 2025, the company brings togethe... Read More
